AMZN
Amazon.com, Inc.
AMZN has the edge over XPEV overall, supported by stronger valuation and stronger modeled upside.
XPEV
XPeng Inc.
XPEV offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
XPEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Unavailable |
XPEV's revenue and cash flow are currently stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
XPEV PE Valuation
XPEV has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
XPEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect XPEV's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over XPEV on earnings quality, reporting a profit while its opponent remains loss making.
XPEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.93 | -$0.25 |
| Q1 2026 | -$0.58 | +$0.23 |
| Q4 2025 | -$0.12 | +$0.80 |
| Q3 2025 | -$0.45 | +$0.47 |
| Q2 2025 | -$0.68 | +$0.63 |
| Q1 2025 | -$0.81 | +$0.79 |
| Q4 2024 | -$0.92 | +$0.87 |
| Q3 2024 | -$0.92 | +$1.07 |
XPEV is still losing money, but far less than before: $0.93 per share over the past year, against $1.99 at its worst in late 2023.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN's revenue has grown year over year every quarter since late 2020: $202B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over XPEV on profitability, with a higher operating margin.
XPEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3B | +7.7% |
| Q1 2026 | $1.9B | -18% |
| Q4 2025 | $3.3B | +36% |
| Q3 2025 | $3.1B | +102% |
| Q2 2025 | $2.7B | +125% |
| Q1 2025 | $2.4B | +141% |
| Q4 2024 | $2.4B | +23% |
| Q3 2024 | $1.5B | +18% |
XPEV's revenue is growing: $3B last quarter, up 7.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6.7% | -1.6 points |
| Q1 2026 | -16% | -9.6 points |
| Q4 2025 | -4.2% | +5.5 points |
| Q3 2025 | -3.7% | +15 points |
| Q2 2025 | -5.1% | +15 points |
| Q1 2025 | -6.6% | +19 points |
| Q4 2024 | -9.7% | +6.1 points |
| Q3 2024 | -18% | +19 points |
XPEV's operating margin was −6.7% last quarter, down 1.6 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
XPEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
XPEV's free cash flow was $0 over the past year, against $0 the year before.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
XPEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +541K shares |
| 1 year | -49% | -467M shares |
| 3 years | -45% | -383M shares |
| 5 years | -44% | -377M shares |
| Available history | -44% | -377M shares |
XPEV has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
XPEV hasn't bought back shares in the past year.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
XPEV Net Leverage
XPEV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
XPEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 17.7 | Oversold |
XPEV's weekly RSI is 36 (neutral) and its Stochastic is 18 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
XPEV PE vs Consumer Cyclical Sector
XPEV has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over XPEV on trend strength, trading above more of its moving averages.
XPEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.56 | 1% below |
| 20 week MA | $11.1 | 14% below |
| 50 week MA | $14.9 | 37% below |
| 100 week MA | $17.2 | 45% below |
| 200 week MA | $14.2 | 33% below |
XPEV is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over XPEV on returns for 2026, with the stronger performance.
XPEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $41.9 | +84% |
| 2021 | $41.9 | $46.1 | +10% |
| 2022 | $46.1 | $10.1 | -78% |
| 2023 | $10.1 | $14.6 | +45% |
| 2024 | $14.6 | $12.6 | -13% |
| 2025 | $12.6 | $20.8 | +65% |
| 2026 YTD | $20.8 | $9.46 | -54% |
XPEV is down 54% so far in 2026, after finishing higher in four of the previous six years.